Article

Daily Medication Pearl: Ponesimod (Ponvory)

Ponesimod (Ponvory) is indicated for the treatment of relapsing forms of multiple sclerosis.

Medication Pearl of the Day: Ponesimod (Ponvory)

Indication: Ponesimod (Ponvory) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Insight:

  • Dosing: The recommended maintenance dosage is 20 mg taken orally once daily.
  • Dosage forms: Tablets 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, and 20 mg.
  • Adverse events: Most common adverse reactions (incidence at least 10%) are upper respiratory tract infection, hepatic transaminase elevation, and hypertension.
  • Mechanism of action: Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1.
  • Manufacturer: Janssen Pharma

Source

PONVORY-pi.pdf (janssenlabels.com)

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Monoclonal antibodies are used to treat lung cancer. They are created in a lab and designed to target specific proteins on cancer cells, stopping them from growing and dividing.
Gene therapy in lung cancer (LC) - isometric view 3d illustration
© 2025 MJH Life Sciences

All rights reserved.